Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma

Medical Oncology

Volumn 31, Issue 2, 2014, Pages

  Mu, Yisila ^a   Zhang, Haoshaqiang ^a   Che, Lixin ^a   Li, Kun ^a  

^a Xinjiang Uygur Autonomous Region Hospital   (China)

Author keywords

Clinicopathologic features; Disease free survival; Ezrin; MicroRNA 183; Osteosarcoma; Overall survival

Indexed keywords

EZRIN; MESSENGER RNA; MICRORNA; MICRORNA 183; UNCLASSIFIED DRUG; CYTOSKELETON PROTEIN; MIRN183 MICRORNA, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE TISSUE; CANCER PATIENT; CANCER PROGNOSIS; CHILD; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; YOUNG ADULT; BONE; BONE TUMOR; CANCER GRADING; COMPARATIVE STUDY; DISEASE COURSE; FOLLOW UP; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; BONE AND BONES; BONE NEOPLASMS; CHILD; CYTOSKELETAL PROTEINS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891770814     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0821-3     Document Type: Article

References (35)

1. Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398-406.
2. Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137:89-99.
3. Osborne TS, Khanna C. A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol. 2012;146:132-42.
4. Poletajew S, Fus L, Wasiutyński A. Current concepts on pathogenesis and biology of metastatic osteosarcoma tumors. Ortop Traumatol Rehabil. 2011;13:537-45.
5. Posthuma De Boer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis. 2011;28: 493-503.
6. Chou J, Shahi P, Werb Z. MicroRNA-mediated regulation of the tumor microenvironment. Cell Cycle. 2013;12:3262-71.
7. Miao J, Wu S, Peng Z, Tania M, Zhang C. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol. 2013;34:2093-8.
8. Zhou G, Shi X, Zhang J, Wu S, Zhao J. MicroRNAs in osteosarcoma: from biological players to clinical contributors, a review. J Int Med Res. 2013;41:1-12.
9. Liang W, Gao B, Fu P, Xu S, Qian Y, Fu Q. The miRNAs in the pathgenesis of osteosarcoma. Front Biosci. 2013;18: 788-94.
10. Tian Q, Jia J, Ling S, Liu Y, Yang S, Shao Z. A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol. 2013. doi:10.1016/j.ejso.2013.08.024.
11. Tang M, Lin L, Cai H, Tang J, Zhou Z. MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma. Onco Targets Ther. 2013;6:833-8.
12. Yuan J, Chen L, Chen X, Sun W, Zhou X. Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res. 2012;40:2090-7.
13. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998;58:2170-5.
14. Motoyama K, Inoue H, Takatsuno Y, et al. Over-and underexpressed microRNAs in human colorectal cancer. Int J Oncol. 2009;34:1069-75.
15. Lin WM, Baker AC, Beroukhim R, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008;68:664-73.
16. Zhou T, Zhang G-J, Zhou H, Xiao H-X, Li Y. Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. Eur J Gastroenterol Hepatol. 2013. doi:10.1097/MEG. 0000000000000002.
17. Ueno K, Hirata H, Shahryari V, et al. MicroRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer. 2013;108:1659-67.
18. Tanaka H, Sasayama T, Tanaka K, et al. MicroRNA-183 upregulates HIF-1α by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells. J Neurooncol. 2013;111:273-83.
19. Wang G, Mao W, Zheng S. MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett. 2008;582:3663-8.
20. Zhao H, Guo M, Zhao G, et al. miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. Int J Mol Med. 2012;30:1013-20.
21. Zhu J, Feng Y, Ke Z, et al. Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol. 2012;180:2440-51.
22. Shang X, Wang Y, Zhao Q, et al. siRNAs target sites selection of ezrin and the influence of RNA interference on ezrin expression and biological characters of osteosarcoma cells. Mol Cell Biochem. 2012;364:363-71.
23. Li H, Min D, Zhao H, et al. The prognostic role of ezrin immunoexpression in osteosarcoma: a meta-analysis of published data. PLoS ONE. 2013;8:e64513.
24. Wang Z, He ML, Zhao JM, Qing HH, Wu Y. Meta-analysis of associations of the ezrin gene with human osteosarcoma response to chemotherapy and prognosis. Asian Pac J Cancer Prev. 2013;14:2753-8.
25. Ren L, Hong SH, Chen QR, et al. Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma. Cancer Res. 2012;72:1001-12.
26. Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer. 2003;97: 3068-75.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25:402-8.
28. Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398-406.
29. Jörgren F, Nilbert M, Rambech E, Bendahl PO, Lindmark G. Ezrin expression in rectal cancer predicts time to development of local recurrence. Int J Colorectal Dis. 2012;27:893-9.
30. Arumugam P, Partelli S, Coleman SJ, et al. Ezrin expression is an independent prognostic factor in gastro-intestinal cancers. J Gastrointest Surg. 2013;17:2082-91.
31. Gschwantler-Kaulich D, Natter C, Steurer S, et al. Increase in ezrin expression from benign to malignant breast tumours. Cell Oncol. 2013;36:485-91.
32. Saito S, Yamamoto H, Mukaisho K, et al. Mechanisms underlying cancer progression caused by ezrin overexpression in tongue squamous cell carcinoma. PLoS ONE. 2013;8:e54881.
33. Lee HW, Kim EH, Oh MH. Clinicopathologic implication of ezrin expression in non-small cell lung cancer. Korean J Pathol. 2012;46:470-7.
34. Fadiel A, Chen Z, Ulukus E, Ohtani K, Hatami M, Naftolin F. Ezrin overexpression by transformed human ovarian surface epithelial cells, ovarian cleft cells, and serous ovarian adenocarcinoma cells. Reprod Sci. 2012;19:797-805.
35. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005;65:2406-11.